Literature DB >> 28104464

Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

Marjolein Wentink1, Virgil Dalm2, Arjan C Lankester3, Pauline A van Schouwenburg1, Liesbeth Schölvinck4, Tomas Kalina5, Radana Zachova6, Anna Sediva6, Annechien Lambeck4, Ingrid Pico-Knijnenburg1, Jacques J M van Dongen7, Malgorzata Pac8, Ewa Bernatowska8, Martin van Hagen2, Gertjan Driessen9, Mirjam van der Burg10.   

Abstract

BACKGROUND: Mutations in PIK3CD and PIK3R1 cause activated PI3K-δ syndrome (APDS) by dysregulation of the PI3K-AKT pathway.
METHODS: We studied precursor and peripheral B-cell differentiation and apoptosis via flowcytometry. Furthermore, we performed AKT-phosphorylation assays and somatic hypermutations (SHM) and class switch recombination (CSR) analysis.
RESULTS: We identified 13 patients of whom 3 had new mutations in PIK3CD or PIK3R1. Patients had low total B-cell numbers with increased frequencies of transitional B cells and plasmablasts, while the precursor B-cell compartment in bone marrow was relatively normal. Basal AKT phosphorylation was increased in lymphocytes from APDS patients and natural effector B cells where most affected. PI3K mutations resulted in altered SHM and CSR and increased apoptosis.
CONCLUSIONS: The B-cell compartment in APDS patients is affected by the mutations in PI3K. There is reduced differentiation beyond the transitional stage, increased AKT phosphorylation and increased apoptosis. This B-cell phenotype contributes to the clinical phenotype.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  APDS; Apoptosis; B cells; B-cell differentiation; PI3Kδ

Mesh:

Substances:

Year:  2017        PMID: 28104464     DOI: 10.1016/j.clim.2017.01.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  30 in total

1.  Dysregulated actin dynamics in activated PI3Kδ syndrome.

Authors:  Jacqueline G Wallace; Pedro Zambrano-Rodas; Wilmer Córdova-Calderón; Santiago Estrada-Turriate; Daniel Mendoza-Quispe; Yesenia Limache Ontiveros; Raif S Geha; Janet Chou; Craig D Platt
Journal:  Clin Immunol       Date:  2019-11-21       Impact factor: 3.969

Review 2.  Immune Dysregulation and Disease Pathogenesis due to Activating Mutations in PIK3CD-the Goldilocks' Effect.

Authors:  Stuart G Tangye; Julia Bier; Anthony Lau; Tina Nguyen; Gulbu Uzel; Elissa K Deenick
Journal:  J Clin Immunol       Date:  2019-03-25       Impact factor: 8.317

3.  Induction of metabolic quiescence defines the transitional to follicular B cell switch.

Authors:  Jocelyn R Farmer; Hugues Allard-Chamard; Na Sun; Maimuna Ahmad; Alice Bertocchi; Vinay S Mahajan; Toby Aicher; Johan Arnold; Mark D Benson; Jordan Morningstar; Sara Barmettler; Grace Yuen; Samuel J H Murphy; Jolan E Walter; Musie Ghebremichael; Alex K Shalek; Facundo Batista; Robert Gerszten; Shiv Pillai
Journal:  Sci Signal       Date:  2019-10-22       Impact factor: 8.192

4.  PI3K Isoforms in B Cells.

Authors:  Elissa K Deenick; Julia Bier; Anthony Lau
Journal:  Curr Top Microbiol Immunol       Date:  2022       Impact factor: 4.737

5.  Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.

Authors:  V Koneti Rao; Sharon Webster; Virgil A S H Dalm; Anna Šedivá; P Martin van Hagen; Steven Holland; Sergio D Rosenzweig; Andreas D Christ; Birgitte Sloth; Maciej Cabanski; Aniket D Joshi; Stefan de Buck; Julie Doucet; Danilo Guerini; Christoph Kalis; Ilona Pylvaenaeinen; Nicolas Soldermann; Anuj Kashyap; Gulbu Uzel; Michael J Lenardo; Dhavalkumar D Patel; Carrie L Lucas; Christoph Burkhart
Journal:  Blood       Date:  2017-09-29       Impact factor: 22.113

Review 6.  Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency.

Authors:  Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robyn E O'Hehir; Menno C van Zelm
Journal:  Cell Mol Immunol       Date:  2020-08-17       Impact factor: 11.530

Review 7.  Activated PI3Kinase Delta Syndrome-A Multifaceted Disease.

Authors:  Romane Thouenon; Nidia Moreno-Corona; Lucie Poggi; Anne Durandy; Sven Kracker
Journal:  Front Pediatr       Date:  2021-06-25       Impact factor: 3.418

8.  Two Monogenetic Disorders, Activated PI3-Kinase-δ Syndrome 2 and Smith-Magenis Syndrome, in One Patient: Case Report and a Literature Review of Neurodevelopmental Impact in Primary Immunodeficiencies Associated With Disturbed PI3K Signaling.

Authors:  Nidia Moreno-Corona; Loïc Chentout; Lucie Poggi; Romane Thouenon; Cecile Masson; Melanie Parisot; Lou Le Mouel; Capucine Picard; Isabelle André; Marina Cavazzana; Laurence Perrin; Anne Durandy; Saba Azarnoush; Sven Kracker
Journal:  Front Pediatr       Date:  2021-06-24       Impact factor: 3.418

Review 9.  Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity.

Authors:  Pu Sun; Ling-Hua Meng
Journal:  Acta Pharmacol Sin       Date:  2020-09-16       Impact factor: 7.169

10.  Clinical Manifestations and Outcomes of Activated Phosphoinositide 3-Kinase δ Syndrome from the USIDNET Cohort.

Authors:  Jessica Oh; Elizabeth Garabedian; Ramsay Fuleihan; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol Pract       Date:  2021-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.